切换至 "中华医学电子期刊资源库"

中华腔镜泌尿外科杂志(电子版) ›› 2024, Vol. 18 ›› Issue (03) : 219 -224. doi: 10.3877/cma.j.issn.1674-3253.2024.03.004

临床研究

腹腔镜肾部分切除术:肾癌合并肾静脉癌栓的新选择
张超1, 过菲1, 王富博1, 叶宸1, 杨悦1, 杨波1,()   
  1. 1. 200433 上海,长海医院泌尿外科
  • 收稿日期:2023-10-13 出版日期:2024-06-01
  • 通信作者: 杨波
  • 基金资助:
    国家自然科学基金(82000654)

Laparoscopic partial nephrectomy: a new choice for the treatment of renal cancer with renal vein tumor thrombus

Chao Zhang1, Fei Guo1, Fubo Wang1, Chen Ye1, Yue Yang1, Bo Yang1,()   

  1. 1. Department of Urology, Changhai Hospital, Shanghai 200433, China
  • Received:2023-10-13 Published:2024-06-01
  • Corresponding author: Bo Yang
引用本文:

张超, 过菲, 王富博, 叶宸, 杨悦, 杨波. 腹腔镜肾部分切除术:肾癌合并肾静脉癌栓的新选择[J]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(03): 219-224.

Chao Zhang, Fei Guo, Fubo Wang, Chen Ye, Yue Yang, Bo Yang. Laparoscopic partial nephrectomy: a new choice for the treatment of renal cancer with renal vein tumor thrombus[J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(03): 219-224.

目的

探索肾部分切除术治疗肾癌合并肾静脉癌栓的可能性。

方法

回顾性分析2018年1月至2021年12月同一术者进行的因肾脏恶性肿瘤行腹腔镜肾部分切除术的病例,其中6例患者伴有肾静脉癌栓,男性4例,女性2例,3例肿瘤位于左肾,3例位于右肾。

结果

肿瘤直径1.8~3.5 cm。5例保肾成功,1例患者因癌栓充满肾静脉主干,且距离肿瘤较远,中转肾癌根治术,1例孤立肾患者,予以术中冰水降温。手术时间129~195 min,热缺血时间24~32 min,术中出血量100~200 ml,5例保肾成功的患者切缘均未见肿瘤残余,1例患者术后出现轻度血尿,予以膀胱持续冲洗后好转。所有患者病理均提示肾透明细胞癌,经18~51个月的随访,未见肿瘤复发。

结论

对于高选择性的肾癌伴肾静脉癌栓的患者,腹腔镜肾部分切除术可能是一种新的可选治疗方式,但由于目前数据有限,尚无法确切评估其安全性和有效性,肾癌根治术依然是此类患者的标准治疗术式。

Objective

To explore the possibility of partial nephrectomy in the treatment of renal cancer with renal vein tumor thrombus.

Methods

From January 2018 to December 2021, laparoscopic partial nephrectomy was carried out in Shanghai Changhai Hospital for renal malignant tumors. Six of these patients had renal cell carcinoma with renal vein tumor thrombus. Four were males and 2 were females. Three tumors located in the left kidney and 3 in the right kidney.

Results

The tumor was 1.8-3.5 cm in diameter. Five patients were successful in sparing the kidney. In one case, the renal vein was full of thrombus and the distance from the tumor to thrombus was far away. Therefore, the surgery was converted to radical nephrectomy. In one patient with solitary kidney, iced water was applied during surgery. The operation time was 129-195 min, the warm ischemia time was 24-32 min, and the intraoperative bleeding volume was 100-200 ml. No positive margin was detected in the patients with successfully kidney sparing. One patient had mild hematuria after operation, and it was improved by continuous bladder irragation. Renal clear cell carcinoma was diagnosed in all patients, and no recurrence occured after 18 to 51 months of follow-up.

Conclusions

Laparoscopic partial nephrectomy may be a new alternative treatment for highly selective patients with renal cell carcinoma and renal vein tumor thrombus. However, due to the limited data at present, the safety and effectiveness of laparoscopic partial nephrectomy can not be evaluated accurately. Radical nephrectomy is still the standard treatment for such patients.

表1 六例肾癌合并肾静脉癌栓患者的详细信息
图1 肾透明细胞癌合并0a级癌栓典型病例的影像及手术图片注:a示癌栓位于肾静脉属支;b示术前三维重建可见静脉属支4支,其中1支内见癌栓;c示术中见癌栓位于静脉属支;d示肾癌合并静脉癌栓大体标本;e示术后6个月CT检查结果;f示术后6个月CT三维重建,可见静脉属支3支;0a级癌栓指癌拴仅位于肾静脉属支
图2 1例肾透明细胞癌合并0c级癌栓的大体标本注:癌栓充满肾静脉截面,且肿瘤远离肾门
表2 肾癌合并肾静脉癌栓患者行保肾手术相关研究
[1]
Wang BR, Ou YC, Huang LH, et al. Robotic partial nephrectomy for renal tumor: the pentafecta outcomes of a single surgeon experience[J]. Asian J Surg, 2023, 46(9): 3587-3592.
[2]
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[3]
Chen K, Liu Z, Li Y, et al. Long-term outcomes after cytoreductive nephrectomy and thrombectomy of patients with metastatic renal cell carcinoma with venous tumor thrombus: a retrospective study from a large Chinese center[J]. World J Surg Oncol, 2023, 21(1): 170.
[4]
Li KP, Chen SY, Wang CY, et al. Perioperative and oncologic outcomes of minimally-invasive surgery for renal cell carcinoma with venous tumor thrombus: a systematic review and meta-analysis of comparative trials[J]. Int J Surg, 2023, 109(9): 2762-2773.
[5]
Abel EJ, Masterson TA, Karam JA, et al. Predictive nomogram for recurrence following surgery for nonmetastatic renal cell cancer with tumor thrombus[J]. J Urol, 2017, 198(4): 810-816.
[6]
Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on renal cell carcinoma: the 2022 update[J]. Eur Urol, 2022, 82(4): 399-410.
[7]
Hoeh B, Flammia RS, Hohenhorst L, et al. Effect of inferior vena cava tumor thrombus on overall survival in metastatic renal cell carcinoma patients treated with cytoreductive nephrectomy[J]. Eur Urol Open Sci, 2022, 44: 94-101.
[8]
Neves RJ, Zincke H. Surgical treatment of renal cancer with vena cava extension[J]. Br J Urol, 1987, 59(5): 390-395.
[9]
Zisman A, Wieder JA, Pantuck AJ, et al. Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy[J]. J Urol, 2003, 169(3): 909-916.
[10]
Martínez-Salamanca JI, Huang WC, Millán I, et al. Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension[J]. Eur Urol, 2011, 59(1): 120-127.
[11]
Tian X, Hong P, Liu Z, et al. En bloc retroperitoneal laparoscopic radical nephrectomy with inferior vena cava thrombectomy for renal cell carcinoma with level 0 to II venous tumor thrombus: a single-center experience[J]. Cancer, 2020, 126(Suppl 9): 2073-2078.
[12]
Wang B, Huang Q, Liu K, et al. Robot-assisted level III-IV inferior vena cava thrombectomy: initial series with step-by-step procedures and 1-yr outcomes[J]. Eur Urol, 2020, 78(1): 77-86.
[13]
Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data[J]. J Urol, 2002, 167(1): 57-60.
[14]
Fergany AF, Hafez KS, Novick AC. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup[J]. J Urol, 2000, 163(2): 442-445.
[15]
Ljungberg B, Bensalah K, Canfield S, et al. EAU Guidelines on renal cell carcinoma: 2014 update[J]. Eur Urol, 2015, 67(5): 913-924.
[16]
Mir MC, Derweesh I, Porpiglia F, et al. Partial nephrectomy versus radical nephrectomy for clinical T1b and T2 renal tumors: a systematic review and meta-analysis of comparative studies[J]. Eur Urol, 2017, 71(4): 606-617.
[17]
Wang F, Zhang C, Guo F, et al. Navigation of intelligent/interactive qualitative and quantitative analysis three-dimensional reconstruction technique in laparoscopic or robotic assisted partial nephrectomy for renal hilar tumors[J]. J Endourol, 2019, 33(8): 641-646.
[18]
Abdel Raheem A, Alatawi A, Soto I, et al. Robot-assisted partial nephrectomy confers excellent long-term outcomes for the treatment of complex cystic renal tumors: median follow up of 58 months[J]. Int J Urol, 2016, 23(12): 976-982.
[19]
Gu L, Liu K, Shen D, et al. Comparison of robot-assisted and laparoscopic partial nephrectomy for completely endophytic renal tumors: a high-volume center experience[J]. J Endourol, 2020, 34(5): 581-587.
[20]
Capitanio U, Zini L, Perrotte P, et al. Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study[J]. Urology, 2008, 72(5): 1090-1095.
[21]
Lenis AT, Salmasi AH, Donin NM, et al. Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma[J]. Urol Oncol, 2018, 36(2): 78.e21-78.e78.e28.
[22]
Angermeier KW, Novick AC, Streem SB, et al. Nephron-sparing surgery for renal cell carcinoma with venous involvement[J]. J Urol, 1990, 144(6): 1352-1355.
[23]
Pruthi RS, Angell SK, Brooks JD, et al. Partial nephrectomy and caval thrombectomy for renal cell carcinoma in a solitary kidney with an accessory renal vein[J]. BJU Int, 1999, 83(1): 142-143.
[24]
Tollefson MK, Kawashima A, Blute ML. In situ partial nephrectomy and tumor thrombectomy for renal cell carcinoma with level II vena cava extension in a solitary kidney[J]. Urology, 2005, 66(4): 882.
[25]
Woldu SL, Barlow LJ, Patel T, et al. Single institutional experience with nephron-sparing surgery for pathologic stage T3bNxM0 renal cell carcinoma confined to the renal vein[J]. Urology, 2010, 76(3): 639-642.
[26]
Kim EH, Jain S, Benway BM, et al. Partial nephrectomy in two patients with known T3a tumours involving the renal vein[J]. BJU Int, 2012, 109(9): 1345-1348.
[27]
Abaza R, Angell J. Robotic partial nephrectomy for renal cell carcinomas with venous tumor thrombus[J]. Urology, 2013, 81(6): 1362-1367.
[28]
Marra G, Gontero P, Brattoli M, et al. Is imperative partial nephrectomy feasible for kidney cancer with venous thrombus involvement? Outcomes of 42 cases and matched pair analysis with a large radical nephrectomy cohort[J]. Urol Oncol, 2018, 36(7): 339.e1-339339.e8.
[29]
Shchukin D, Lisova G, Khareba G, et al. Nephron-sparing surgery in patients with renal cell carcinoma extending to the main renal vein: intrarenal and extrarenal thrombectomy[J]. Georgian Med News, 2019(297): 23-30.
[1] 张卫平, 王婧玲, 刘志兴, 陈莉, 谌芳群. 肾透明细胞癌高帧频超声造影时间-强度曲线特征分析[J]. 中华医学超声杂志(电子版), 2023, 20(09): 916-922.
[2] 朱显钟, 李金雨, 于忠英, 温路生. 淋巴结平均直径与无淋巴结转移肾癌病理特征及预后关系研究[J]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(02): 146-151.
[3] 赵佳晖, 王永兴, 彭涛, 李明川, 魏德超, 韩毅力, 侯铸, 姜永光, 罗勇. 后腹腔镜根治性肾切除手术时间延长和术中出血量增多的影响因素分析[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(06): 575-580.
[4] 张圣平, 邓琼, 张颖, 张建文, 梁辉, 王铸. 孤儿核受体HNF4α在肾透明细胞癌中的表达及意义[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(06): 627-632.
[5] 刘阳阳, 王梁, 戴志红, 郝建戈, 张力仁, 刘志宇. 腹膜后去分化脂肪肉瘤合并左肾透明细胞癌一例报告[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(04): 412-414.
[6] 杨春亭, 毛云华, 罗云, 刘博皓. 孤立肾合并肾混合性上皮间质肿瘤一例报告并文献复习[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(04): 407-409.
[7] 戴志红, 刘志宇. 囊性肾癌肾部分切除术的实践与思考 [J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(04): 423-423.
[8] 李国良, 吴凡, 李浩民, 江俊斌, 郭泽雄, 卓育敏, 马鑫, 赖彩永. 抽栓技术在完全腹腔镜左肾癌合并Ⅳ级腔静脉癌栓取出术的应用[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(04): 403-406.
[9] 董翔, 马文亮, 纪长威, 李笑弓, 张古田, 甘卫东, 郭宏骞. 回顾性评估肾细胞癌假包膜状态及其影响因素[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(04): 356-360.
[10] 刘麒, 曾弘, 徐子昕, 方超, 黄铭, 郑俊炯, 吴少旭, 钟广正, 林天歆, 黄健, 董文. 乳头状肾细胞癌单中心11年临床诊治与预后分析[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(04): 351-355.
[11] 陈伟, 周骏, 梁朝朝. 机器人辅助腹腔镜下右肾部分切除术治疗后肾腺瘤一例报告[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(03): 293-293.
[12] 唐国军, 洪余德, 赵崇玉, 李辽源. 基于TCGA数据库Wnt相关长链非编码RNA构建肾乳头状细胞癌预后模型[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(03): 270-275.
[13] 卓然, 朱逸琪, 逯艳文, 马文亮, 郭宏骞, 甘卫东. 性别对Xp11.2易位型肾癌及肾透明细胞癌临床特征的影响[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(02): 105-109.
[14] 张晓飞, 许慧芬, 韩开宇. 经EBUS-TBNA诊断肾透明细胞癌纵膈淋巴结转移一例[J]. 中华肺部疾病杂志(电子版), 2023, 16(05): 755-756.
[15] 李静波, 朱嘉宁, 宋禄达, 罗渝昆, 李秋洋. 多模态超声成像技术在肾肿瘤诊断中的应用进展[J]. 中华肾病研究电子杂志, 2023, 12(06): 349-353.
阅读次数
全文


摘要